Mountain View Clinical Research | Denver, CO

Research site

(Unclaimed)

Location

3955 East Exposition Avenue, Suite 104, Denver, Colorado, United States of America

Site insights

Top conditions

Top treatments

Ponesimod

AD109

Pregabalin

Naltrexone Hydrochloride

oxymorphone

Teriflunomide

Lu AG06466

Psilocybin

Lyrica

Lubiprostone

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 26 total trials

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) (FENhance)

A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible parti...

Active, not recruiting

Relapsing Multiple Sclerosis

Drug: Placebo

Drug: Fenebrutinib

Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder

The study's purpose its to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compu...

Enrolling

Obsessive-Compulsive Disorder

Drug: Placebo

Drug: Troriluzole

ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder

The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)

Enrolling

Generalized Anxiety Disorder

Drug: Placebo

Drug: ENX-102

Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only

Obsessive Compulsive Disorder

Drug: Troriluzole (BHV-4157)

Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obs...

Active, not recruiting

OSA

Drug: Placebo

Drug: AD109

Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients

This study is to characterize the safety and tolerability of an investigational drug called DONQ52 and consists of a single ascending dose part (Part...

Active, not recruiting

Celiac Disease

Drug: Placebo

Drug: DONQ52